Evidence map›Paper›PMID 38409373›Full record

Trial reportScientific reports2024

Neuroinflammation following anti-parkinsonian drugs in early Parkinson's disease: a longitudinal PET study.

Tatsuhiro Terada, Tomoyasu Bunai, Takanori Hashizume, Takashi Matsudaira, Masamichi Yokokura, Hirotsugu Takashima, Takashi Konishi, Tomokazu Obi, Yasuomi Ouchi

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Neuroprotection in Parkinson Disease.Neurology and therapy · 2025
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Tatsuhiro TeradaDepartment of Biofunctional Imaging, Preeminent Medical Photonics Education and Research Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.
Tomoyasu BunaiDepartment of Biofunctional Imaging, Preeminent Medical Photonics Education and Research Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.
Takanori HashizumeLaboratory of Drug Metabolism and Pharmacokinetics, Faculty of Pharmacy, Osaka Ohtani University, Tondabayashi, Japan.
Takashi MatsudairaDepartment of Biofunctional Imaging, Preeminent Medical Photonics Education and Research Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.
Masamichi YokokuraDepartment of Psychiatry, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hirotsugu TakashimaDepartment of Biofunctional Imaging, Preeminent Medical Photonics Education and Research Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.
Takashi KonishiDepartment of Neurology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
Tomokazu ObiDepartment of Neurology, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.
Yasuomi OuchiDepartment of Biofunctional Imaging, Preeminent Medical Photonics Education and Research Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan. ouchi@hama-med.ac.jp.
Hamamatsu University School of Medicine · JPHamamatsu Medical Center · JPNational Epilepsy Center · JPOsaka Ohtani University · JPShizuoka Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The progression of neuroinflammation after anti-parkinsonian therapy on the Parkinson's disease (PD) brain and in vivo evidence of the therapy purporting neuroprotection remain unclear. To elucidate this, we examined changes in microglial activation, nigrostriatal degeneration, and clinical symptoms longitudinally after dopamine replacement therapy in early, optimally-controlled PD patients with and without zonisamide treatment using positron emission tomography (PET). We enrolled sixteen PD patients (Hoehn and Yahr stage 1-2), and age-matched normal subjects. PD patients were randomly divided into two groups: one (zonisamide

Indexed as

Parkinson DiseaseBrainDopamine Plasma Membrane Transport ProteinsHumansNeuroinflammatory DiseasesPositron-Emission TomographyZonisamideDopamine Plasma Membrane Transport ProteinsZonisamideDopamine transporterNeuroinflammationParkinson’s disease (PD)Positron emission tomographyZonisamide

Identifiers

PMID38409373
PMCPMC10897150
OpenAlexW4392194548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.